A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease

UCB Biopharma SRL2 sites in 2 countries62 target enrollmentDecember 14, 2020

ConditionsParkinson's Disease

InterventionsUCB7853 Placebo

DrugsUCB7853

Overview

Phase: Phase 1
Intervention: UCB7853
Conditions: Parkinson's Disease
Sponsor: UCB Biopharma SRL
Enrollment: 62
Locations: 2
Primary Endpoint: Incidence of Treatment-emergent Adverse Events (TEAEs) in healthy male participants
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The primary purpose of the study is to evaluate the safety and tolerability of single ascending doses of UCB7853 in healthy male study participants and to evaluate the safety and tolerability of multiple ascending doses of UCB7853 administered in study participants with Parkinson's Disease (PD)

Registry

clinicaltrials.gov

Start Date

December 14, 2020

End Date

July 20, 2023

Last Updated

last year

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

UCB Biopharma SRL

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Part 1 (healthy participants):
•Participant must be male and 18 to 55 years of age inclusive
•Body weight within 50 kg to 110 kg and body mass index (BMI) within the range 18.0 to 30.0 kg/m\^2 (inclusive)
•Participant must be healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring
•Participant has clinical laboratory test results within the reference ranges of the laboratory
•Part 2 (participants with Parkinson's Disease):
•Participant must be 40 to 80 years of age, inclusive, at the time of signing the informed consent form (ICF)
•Participant may be male or female
•Participant must have body weight of between 50 and 110 kg and a body mass index within the range of 18 to 32 kg/m\^2 (inclusive)
•Participant must have a clinical diagnosis of Parkinson's disease (PD) according to the Movement Disorders Society criteria. The following diagnostic criteria must be met: Bradykinesia AND at least ONE of the following: muscular rigidity or resting tremor

Exclusion Criteria

•Part 1 (healthy participants):
•Participant has a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, pancreatic, musculoskeletal, genitourinary, immunological, dermatological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data
•Participant has a known hypersensitivity to any components of the study medication or comparative drugs
•Participant has any clinically relevant abnormal findings in physical examination, laboratory tests, or vital signs, which, in the opinion of the Investigator, may place the participant at risk because of participation in the study
•Participant has any clinically relevant brain magnetic resonance imaging (MRI) abnormality at Screening
•Part 2 (participants with Parkinson's Disease):
•Participant has a diagnosis of a significant Central nervous system (CNS) disease other than PD or history of epilepsy or seizure disorder other than febrile seizures as a child
•Study participant has a history of levodopa-induced motor fluctuations or dyskinesia expected to interfere with his/her ability to participate in the study
•Participant has a known hypersensitivity to any components of the study medication or comparative drugs
•Study participant has had prior surgical treatment for PD involving intracranial surgery or implantation of a device (including deep brain stimulation) or duodopa

Arms & Interventions

UCB7853

Part 1: Single intravenous infusion of UCB7853 Part 2: Multiple intravenous infusions of UCB7853 at pre-specified time-points

Intervention: UCB7853

Placebo

Part 1: Single intravenous infusion of Placebo Part 2: Multiple intravenous infusions of Placebo at pre-specified time-points

Intervention: Placebo

Outcomes

Primary Outcomes

Incidence of Treatment-emergent Adverse Events (TEAEs) in healthy male participants

Time Frame: From Day 1 to the End of Study Visit (Day 141), Part 1)

A treatment-emergent Adverse Event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.

Incidence of Treatment-emergent Adverse Events (TEAEs) in participants with Parkinson's Disease

Time Frame: From Day 1 to the End of Study Visit (Day 197), Part 2

Secondary Outcomes

Cmax of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1)
Cmax of UCB7853 in serum after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease(Samples will be taken from Day 57 to the End of Study Visit (Day 197), Part 2)
AUC of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1)
AUC(0-t) of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1)
AUC(0-t) of UCB7853 in serum after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease(Samples will be taken from Day 57 to Day 85, Part 2)
tmax of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1)
tmax of UCB7853 in serum after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease(Samples will be taken from from Day 57 to the End of Study Visit (Day 197), Part 2)
t1/2 of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1)
CL of UCB7853 after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from from Day 1 to the End of Study Visit (Day 141), Part 1)
CSF/serum UCB7853 concentration ratio on Day 63 (Part 2)(Day 63 (Part 2))
CL of UCB7853 after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease(Samples will be taken from from Day 57 to Day 85, Part 2)
Vz of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants(Samples will be taken from from Day 1 to the End of Study Visit (Day 141), Part 1)
CSF/serum UCB7853 concentration ratio on Day 7 (Part 1)(Day 7 (Part 1))